Diabetes is a national public health threat in Armenia, and a lack of resources, public awareness, and specialists has been a barrier to effective diabetic eye screening programs. The Armenian EyeCare Project, in conjunction with…
Diabetic retinopathy is an eye complication of diabetes affecting 7.7 million Americans, and this number is projected to increase to more than 14.6 million people by 2030. Many people with diabetes do not receive their…
May 18, 2021 – In a recent Optometry Times article, Dr. A. Paul Chous, MA, OD, FAAO, highlights his experience with Eyenuk’s artificial intelligence (AI) technology in an article titled, “Embrace, don’t fear, AI in…
May 10, 2021 –Frank Cheng, Eyenuk President and CCO, presented in the Ai4 2021 Healthcare Summit on Thursday, May 6, 2021. In his presentation titled “AI is not just the future of healthcare, it is…
The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has US FDA clearance, CE marking as a class IIa medical device in the European Union, and a Health Canada license.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
Exceptional Performance in Pivotal, Prospective, Multi-Center Clinical Trial
Dr. Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a multi part interview series. Click on the video to watch the interview.